Skip to main content
Equibles

CORONA · CORONA Remedies Limited · Documents

Use CORONA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CORONA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,329.70 INR -12.50 (-0.53%) At close · Nov 13
Rebalance outlook locked
Market Cap
142.48B INR
Shares
61.16M
Volume · Nov 13 25.79K Avg daily vol (3M) 45.81K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 2, 2026
2026
Nov 2
Earnings call
Q2 revenue and EBITDA rise 22.2% and 22.3%

CORONA Remedies reported Q2 FY27 revenue of INR441 crores, up 22.2% YoY, while EBITDA rose 22.3% to INR96 crores and H1 PAT grew 22.2% to INR120 crores.

4 source passages
Good morning, everyone. On behalf of Ambit Capital, we welcome you to the 2Q and 1HFY27 earnings conference call of CORONA Remedies Limited. Speaking of performance, revenue for Q2 FY27 stood at INR441 crores versus INR361 crores in Q2 FY26, reflecting a healthy growth of 22.2% YoY revenue growth in Q2. EBITDA for the quarter stood at INR96 crores versus INR78.5 crores in Q2 FY26, a growth of 22.3% on a year-on-year basis. PAT for H1 FY27 stood at INR120 crores, a growth of 22.2% YoY, whereas PAT margin for H1 FY27 stood at 13.9%. Open the document at this passage
Showing 1–3 of 3 documents